Neuralink Aims to Implant Brain Chips in 20,000 People Annually by 2031, Targeting $1B+ Revenue

According to Bloomberg, Elon Musk’s brain-computer interface company, Neuralink Corp., plans to implant its chips in 20,000 people annually by 2031, generating at least $1 billion in annual revenue (approximately RMB 7.16 billion at current exchange rates).

According to the latest materials presented to investors, Neuralink plans to operate approximately five large-scale clinics and launch at least three versions of its device within the next six years. Among these, the “Telepathy” version aims to enable communication between the brain and machines; the “Blindsight” version will focus on helping blind individuals restore their vision; and the “Deep” version is intended for the treatment of tremors and Parkinson’s disease.

Neuralink’s goals reflect Musk’s grand vision for the company and its highly ambitious timeline. Currently, fewer than 10 individuals are known to have participated in clinical trials with Neuralink’s brain implants, and no patients have yet used the device to restore vision or treat Parkinson’s disease.

According to the document, Neuralink expects to obtain regulatory approval for its Telepathy device in the United States by 2029 and plans to perform 2,000 procedures annually, generating at least $100 million (approximately RMB 716 million at current exchange rates) in annual revenue. By 2030, the company plans to launch Blindsight, a chip designed to restore vision, expand its procedure volume to 10,000 cases per year, and achieve annual revenue exceeding $500 million (approximately RMB 3.58 billion at current exchange rates). The document indicates that these figures are based on “a conservative estimate of $50,000 (approximately RMB 358,000 at current exchange rates) in reimbursement per procedure.”

According to PitchBook, Neuralink has raised $1.3 billion (approximately RMB 9.308 billion at the current exchange rate) from investors, and its current valuation has reached $9 billion (approximately RMB 64.443 billion at the current exchange rate).

In recent years, brain-computer interface (BCI) companies such as Neuralink have garnered widespread attention and substantial investment due to their potential medical applications. However, no BCI devices have yet received approval from U.S. regulatory authorities for permanent implantation in humans, as companies are still collecting data on safety and efficacy.

In clinical trials, patients with paralysis have used Neuralink devices to control computers, enabling them to browse the internet, play games, and edit videos. The company has also tested its visual implant in monkeys. Currently, several other brain-implant companies are developing and testing devices capable of reading brain data, but none have received approval from the U.S. Food and Drug Administration (FDA) for commercial permanent implantation.

Source: IT Home

For academic sharing only. If there is any infringement, please leave a message and it will be deleted immediately!

Welcome to the Brain-Computer Interface AI Planet to access more knowledge and resources in fields such as brain-computer interfaces and AI.

For collaboration inquiries, please add WeChat: RoseBCI [Note: Name + Industry/Profession].

   Submissions Welcome   

1. Submissions welcome. For submission inquiries, please contact us on WeChat: RoseBCI

Click to Submit:Guidelines for Submitting Academic News to the Brain-Computer Interface Community

2. To join the community as a part-time creator, please contact us on WeChat: RoseBCI

One-click Triple Action: “Share,” “Like,” and “Watch”

Don't Miss Any Frontier Advances in Brain-Computer Interfaces